Self-Assessment Study Program SASP (2019)
The SASP is the AUA’s most popular study tool for exam preparation!
For over 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists. Developed each year, the SASP is a 150-question, multiple-choice practice examination that addresses the core curriculum of medical knowledge and latest advances in patient care. The SASP may be taken open or closed book, and provides correct answers with detailed answer rationales, and scientific references.
Why is the SASP the AUA's most popular study tool for exam preparation?
Constructed in the same style as the AUA and ABU's multiple-choice examinations—and offered in three convenient formats to meet your unique study preference—SASP is the AUA's most popular study tool for exam preparation. SASP provides participants their scores, the average scores of their peers, and access to answer commentary and scientific references, allowing participants to evaluate their strengths and weaknesses in various clinical areas and enrich their learning experience. Also, it is important to note that over 30% of the content of the ABU Life Long Learning Knowledge Assessment comes directly from SASP!
Offering up to 20 AMA PRA Category 1 Credits™, the SASP also helps to fulfill the CME requirements mandated by the ABU Maintenance of Certification (MOC)© process.
|Online 5-Year Bundle||$495||$645|
Access to the Online, Online Bundle (including prior years) and Q-Stream will begin January 1, 2019. Booklet orders will ship in January.
- Board Candidates
- Advanced Practice Providers
- Physician Assistants
After completing this activity, learners will be able to:
- Assess their knowledge of urology
- Demonstrate an increased knowledge base of urology
- Apply increased knowledge to improve the quality of patient care
- Evaluate strengths and weaknesses in urology upon review of their personalized participant profile
- Develop a personalized study program to improve their foundation of knowledge
- Discuss core knowledge of urology necessary for the ABU's Qualifying and Recertification Examinations
ABU Examination Committee
Stephen A. Boorjian, MD Carl Rosen Professor in Urology, Vice Chair of Research, Department of Urology, Director, Urologic Oncology Fellowship, Mayo Clinic. SUO-CTC Organized Clinical Trial Sponsored by FKD (Scientific Study/Trial).
Robert E. Brannigan, MD Professor, Department of Urology, Chief, Division of Reproductive Surgery and Men’s Health, Director, Andrology Fellowship, Northwestern University, Feinberg School of Medicine. The American Society for Reproductive Medicine (ASRM) (Leadership position; Health Publishing); The American Society for Reproductive Medicine (Leadership position); The National Institutes of Health (Other: NIH/MICHD Date and Safety Monitoring Board Member).
Mark P. Cain, MD Robert Garrett Professor of Pediatric Urology, Department of Urology, Indiana University School of Medicine, Chief of Pediatric Urology, Riley Hospital for Children at IU Health. No Disclosures.
Anthony A. Caldamone, MD Professor of Surgery (Urology) and Pediatrics, The Warren Alpert School of Medicine of Brown University, Head Section of Pediatric Urology, Hasbro Children’s Hospital. No Disclosures.
Sam S. Chang, MD, MBA Patricia and Rodes Hart Endowed Chair in Urologic Surgery, Professor of Urologic Surgery and Oncology, Vanderbilt University Medical Center. Astellas, GLG, Janssen, Tolmar, Altor, BMS, Pfizer (Consultant/Advisor); NIH (Scientific Study/Trial).
Peter E. Clark, MD Professor & Chair, Dept of Urology, Chair, Urologic Oncology Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Galil Medical, Genentech (Consultant/Advisor).
J. Quentin Clemens, MD, MSCI Edward J. McGuire Professor of Urology, Director, Division of Neurourology and Pelvic Reconstructive Surgery, University of Michigan Medical Center. Aquinox, Medtronic (Consultant/Advisor); Allergan (Meeting Participant/Lecturer; UpToDate (Health Publishing); Merck (Investment Interest).
Donna M. Connelly, BS ABU. No Disclosures.
Christopher S. Cooper, MD Professor and Vice Chairman of Urology, Director of Pediatric Urology, Senior Associate Dean for Medical Education, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, University of Iowa Hospitals and Clinics. No Disclosures.
Raymond A. Costabile, MD Jay Y. Gillenwater Professor of Urology and Chairman of Urology Department, University of Virginia. Lilly/Icos (Consultant/Advisor, Scientific Study/Trial); Vivus (Scientific Study/Trial).
Sean P. Elliott, MD, MS Professor and Vice Chairman, Department of Urology and Director of Reconstructive Urology, University of Minnesota. Boston Scientific (Consultant/Advisor); Urotronic (Consultant/Advisor, Scientific Study/Trial); PercuVision (Leadership Position/Investment Interest).
Shelby Englert AUA. No Disclosures.
David A. Ginsberg, MD Professor of Clinical Urology, USC Institute of Urology. Procept, Bioness (Scientific Study/Trial).
Alexander Gomelsky, MD B.E. Trichel Professor and Chairman, Dept of Urology, Louisiana State University Health Shreveport, Director of Female Urology, Neurourology, and Reconstructive Pelvic Surgery, Urology Residency Program Director. No Disclosures.
CD Anthony Herndon, MD Professor of Surgery (Urology), Chief Pediatric Urology, Virginia Commonwealth University, Co-Surgeon-in-Chief, Children’s Hospital of Richmond. No Disclosures.
James Hu, MD, MPH Ronald P. Lynch Professor of Urologic Oncology, Director of the LeFrak Center for Robotic Surgery, Weill Cornell Medicine, New York Presbyterian/Weill Cornell. Genomic Health (Meeting Participant/Lecturer).
Patrick Kerley AUA. No Disclosures.
Andrew T. Jones, PhD Psychometrician, American Board of Surgery. No Disclosures.
Maxwell V. Meng, MD Professor and Chief of Urologic Oncology, Department of Urology, University of California San Francisco. AUA, Urologic Oncology Journal (Health Publishing); Bristol Myers Squibb (Consultant/Advisor).
Rosalia Misseri, MD Professor of Urology, Department of Urology, Indiana University School of Medicine, Pediatric Urology Fellowship Director, Riley Hospital for Children at IU Health. No Disclosures.
Victor Nitti, MD Chair, AUA Office of Education, Professor and Vice Chair, Department of Urology, Professor, Department of Obstetrics and Gynecology, Director, Female Pelvic Medicine and Reconstructive Surgery Program, Female Pelvic Medicine Fellowship Program, New York University School of Medicine. Medtronic (Scientific Study/Trial); Serenity Pharmaceuticals (Investment Interest); Astellas, Allergan (Health Publishing, Scientific Study/Trial).
Hossein Sadeghi-Nejad, MD Professor of Urology, Division of Urology, Rutgers New Jersey Medical School and Hackensack University Medical Center, Hackensack, NJ, Chief of Urology, VA NJ Health Care System. Sexual Medicine Society of North America (Leadership Position); Journal of Sexual Medicine (Health Publishing).
John D. Seigne, MD Associate Professor of Urology, Chief Section of Urology, Geisel School of Medicine, Dartmouth. Johnson & Johnson (Investment Interest).
Ojas Shah, MD George F. Cahill Professor of Urology, Director, Division of Endourology and Stone Disease, Director, Endourology Fellowship; Department of Urology, Columbia University College of Physicians and Surgeons. Applaud Medical (Consultant/Advisor); Boston Scientific, Coloplast (Meeting Participant/Lecturer, Consultant/Advisor); Bristol Myers Squibb, Glaxo Smith Kline, Novartis, NJ Kidney Stone Center (Investment Interest); Elsevier (Health Publishing).
Aseem R. Shukla, MD Director of Minimally Invasive Surgery, Division of Urology, Children’s Hospital of Philadelphia. Associate Professor of Urology, Perelman School of Medicine at the University of Pennsylvania. No Disclosures.
Jessica Siculietano AUA No Disclosures.
Sandip P. Vasavada, MD Urologic Director, Center for Female Pelvic Medicine and Reconstructive Surgery, Professor of Surgery (Urology), Cleveland Clinic Lerner College of Medicine, Glickman Urological Institute, Cleveland Clinic. Medtronic (Meeting Participant/Lecturer); NDI Medical LLC (Investment Interest); Allergan (Consultant/Advisor, Meeting Participant/Lecturer, Scientific Study/Trial); Axonics, Amphora (Consultant/Advisor)
Original Release Date: January 2019 Expiration Date: December 2021
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement: The American Urological Association designates this enduring material for a maximum of 20.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Estimated time for study, test completion, and reference reading for each SASP is 20 hours.
Target Audience: This self-assessment program is designed for practicing urologists, Board candidates, residents and/or physician assistants.
Purpose/Need: Urologists and other health care providers need to assess their knowledge of urology. Identified gaps in this knowledge can lead to individualized, practical educational activities, which will result in improved patient care.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: The material contained in this examination is protected under U.S. Copyright law. Duplication of any part of this examination by any means including, but not limited to, photographic reproduction is a FEDERAL OFFENSE.